Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP Ltd. publication examining how emerging life science programs can translate
In the first half of 2026, the total transaction value of China’s innovative drug BD outbound deals reached $99.7 billion. Among them, three deals worth over
Intelligent disease diagnosis methods are at a critical juncture where rules are rapidly changing. According to Article 25 of the Patent Law, methods for diagnosing and
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Insight, a MeritsIP Ltd. publication examining how emerging life science programs can translate
From patent application to final approval and marketing, a new drug often takes more than ten years. During this period, the time spent on clinical trials
On September 14, the launch ceremony of the 2026 “National Drug Safety Publicity Week” was held in Beijing. Huang Guo, Secretary of the Party Leadership Group
Drug formulation patents are a key link connecting APIs with clinical applications. A compound patent may protect the structure of a molecule, but whether a molecule
# China Launches 2026 National Patent Priority Examination Program to Accelerate High-Value IP Commercialization # China's National Intellectual Property Administration Unveils 2026-Oriented Patent Examination Quality &
siRNA drugs have become one of the fastest-growing innovative therapies in the biopharmaceutical field in recent years. The biggest difference between them and traditional drugs is:
Opening Introduction: In the first half of 2026, the total overseas licensing transaction volume of China’s innovative drugs will exceed $110 billion, accounting for 80% of